Abstract:
OBJECTIVE To review the pharmacoeconomic evaluation methods and findings of sodium-glucose cotransporter-2 (SGLT-2) inhibitors for the treatment of chronic kidney disease.
METHODS Economic evaluation studies of SGLT-2 inhibitors for chronic kidney disease were searched in databases such as PubMed, EMbase, Cochrane Library, CNKI, VIP and Wanfang Database from inception to July, 2024.
RESULTS A total of 14 pharmacoeconomic studies on the use of SGLT-2 inhibitors for treating chronic kidney disease were included, all of which demonstrated that combination therapy with SGLT-2 inhibitors on top of standard treatment was more cost-effective than standard treatment alone.
CONCLUSION Most included studies employ Markov models, and demonstrate that the incorporated SGLT-2 inhibitors including dapagliflozin, canagliflozin and empagliflozin are cost-effective over standard treatment at various willingness-to-pay thresholds.
下载: